Form 4: Bio-Rad Laboratories Executive Acquires Stock Options

Andrew J. Last, EVP and Chief Operating Officer of Bio-Rad Laboratories, acquired 5,891 non-qualified stock options on March 8, 2024.

Summary

• On March 8, 2024, Andrew J. Last, the EVP and Chief Operating Officer of Bio-Rad Laboratories, acquired 5,891 non-qualified stock options.
• The exercise price of these options is $343.76.
• The options vest over four years, with 25% vesting each year on the anniversary of the grant date.
• The expiration date for these options is March 8, 2034.
• Following the transaction, Mr. Last directly owns 5,891 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports a transaction.

Positives

• The acquisition of stock options by a high-ranking executive may indicate confidence in the company's future performance.

Industry Context

This is a routine disclosure of stock option grants to a company executive, a common practice in publicly traded companies to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and life sciences industries.
• Companies like Danaher, Thermo Fisher Scientific, and Agilent Technologies also utilize stock options as part of their executive compensation plans.
• The vesting schedule of four years with 25% vesting annually is a typical vesting arrangement.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates